Global Clinical Trial Disclosure in the U.S. – What Every Clinical Team Needs to KnowJune 18, 2025Project Orbis Expands: A New Era for Global Oncology Drug ApprovalsJune 12, 2025Unlocking the FEI Number: Why Every FDA-Regulated Facility Needs OneJune 4, 2025Fast-Tracking Cures for Rare Diseases: Inside the FDA’s START Pilot ProgramMay 28, 2025Psychedelic Medicine on the Rise: How Regulators Are Shaping Mental Health TreatmentMay 21, 2025Japan’s Legacy in Orphan Drug DevelopmentMay 14, 2025From Animal Models to NAMs-driven AI ToolsApril 30, 2025FDA’s QIDP Designation: The Game-Changer in Antimicrobial Drug InnovationApril 23, 2025RMAT-The Regulatory Catalyst for Accelerating Regenerative Medicine TherapiesApril 16, 2025What is an INTERACT MeetingApril 2, 2025Understanding Protocol Deviations for Clinical Investigations in the USMarch 19, 2025Trump’s Drug Tariff Shockwave: Disruption and Reshaping of Global Pharmaceutical Supply ChainsMarch 12, 2025Navigating the Future: AI in the Drug Product Life Cycle and Regulatory LandscapeFebruary 26, 2025FDA Accelerated Programs in Drug DevelopmentFebruary 13, 2025PMDA Phase1 Waiver Guidelines for Japanese Participation in Global MRCTsFebruary 7, 2025Leadership and Policy Shifts in U.S. Healthcare: Potential Impacts on the Biopharma IndustryJanuary 31, 2025US Agent for FDA Regulated Product ApplicationsJanuary 23, 2025
Trump’s Drug Tariff Shockwave: Disruption and Reshaping of Global Pharmaceutical Supply ChainsMarch 12, 2025
Leadership and Policy Shifts in U.S. Healthcare: Potential Impacts on the Biopharma IndustryJanuary 31, 2025
